Ignite Creation Date:
2025-12-24 @ 6:41 PM
Ignite Modification Date:
2025-12-24 @ 6:41 PM
Study NCT ID:
NCT06685757
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2024-11-11
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000709267', 'term': 'felzartamab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'This is a 2-part trial; Part A will be randomized and placebo-controlled, and Part B will be open-label.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 120}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-12-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2027-06-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-23', 'studyFirstSubmitDate': '2024-11-11', 'studyFirstSubmitQcDate': '2024-11-11', 'lastUpdatePostDateStruct': {'date': '2025-12-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-11-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part A: Percentage of Participants Who Achieve Biopsy-proven Histologic Resolution (BPHR)', 'timeFrame': 'Week 24'}], 'secondaryOutcomes': [{'measure': 'Part A: Microvascular Inflammation (MVI) Score', 'timeFrame': 'Week 24'}, {'measure': 'Part A: Percentage of Participants Who Achieve an MVI Score of 0', 'timeFrame': 'Week 24'}, {'measure': 'Part A: Change from Baseline in Donor-derived Cell-free DNA (dd-cfDNA)', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Part A: Biopsy-based Transcript Composite Score for AMR/MVI', 'timeFrame': 'At Week 24'}, {'measure': 'Part A: Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Part B: Percentage of Participants Who Achieve BPHR', 'timeFrame': 'Weeks 24 and 52'}, {'measure': 'Part B: MVI Score', 'timeFrame': 'Weeks 24 and 52'}, {'measure': 'Part B: Percentage of Participants Who Achieve an MVI Score of 0', 'timeFrame': 'Weeks 24 and 52'}, {'measure': 'Part B: Change from Baseline in dd-cfDNA', 'timeFrame': 'Baseline, Weeks 24 and 52'}, {'measure': 'Part B: Biopsy-based Transcript Composite Score for AMR/MVI', 'timeFrame': 'At Week 52'}, {'measure': 'Part B: Change from Baseline in eGFR', 'timeFrame': 'Baseline, Weeks 24 and 52'}, {'measure': 'Part B: Time to All-cause Allograft Loss', 'timeFrame': 'Up to Week 52'}, {'measure': 'Parts A and B: Number of Participants with Adverse Events', 'timeFrame': 'From time of first dose to end of trial visit (Up to Week 52)'}, {'measure': 'Parts A and B: Number of Participants with Clinically Significant Laboratory Abnormalities', 'timeFrame': 'From time of first dose to end of trial visit (Up to Week 52)'}, {'measure': 'Parts A and B: Number of Participants with Clinically Significant Vital Signs Abnormalities', 'timeFrame': 'From time of first dose to end of trial visit (Up to Week 52)'}, {'measure': 'Parts A and B: Number of Participants with Clinically Significant ECG Abnormalities', 'timeFrame': 'From time of first dose to end of trial visit (Up to Week 52)'}, {'measure': 'Parts A and B: Percentage of Participants with T Cell-mediated Rejection (TCMR) by Biopsy', 'timeFrame': 'Weeks 24 and 52'}, {'measure': 'Parts A and B: Felzartamab Serum Concentration', 'timeFrame': 'Up to Week 52'}, {'measure': 'Parts A and B: Number of Participants with Anti-drug Antibodies (ADAs) against Felzartamab', 'timeFrame': 'Baseline, up to Week 52'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['AMR', 'Felzartamab', 'Kidney Transplant'], 'conditions': ['Antibody-mediated Rejection']}, 'descriptionModule': {'briefSummary': 'In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body\'s immune system can sometimes attack the new kidney.\n\nAntibody-mediated rejection (AMR) is when a person\'s immune system attacks a transplanted organ, like a new kidney. In the person receiving the transplant, their immune system creates specific antibodies. Antibodies are proteins that help the body fight infections. In people with AMR, these antibodies mistakenly see the new organ as a threat and damage its blood vessels. This can cause the new organ to fail.\n\nIn this study, researchers will learn more about how a study drug called felzartamab affects people with AMR. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works in participants with kidney transplants who experience AMR compared to a placebo. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug. All participants in this study will have active AMR or AMR that has lasted for at least 6 months after their kidney transplant.\n\nThe main question that researchers want to answer is:\n\n• How many participants have biopsy results showing that their transplanted kidney tissue looks normal or near normal after 24 weeks of treatment?\n\nResearchers will also learn about:\n\n* How long it takes before the participants\' disease gets worse\n* How long the participants\' urine protein levels stay low\n* Kidney biopsy scores to check for blood vessel inflammation at 6 months and 1 year\n* How many people have no blood vessel inflammation at these times\n* Changes in donor deoxyribonucleic acid (DNA) levels in blood from the start of treatment\n* Biopsy test scores for signs of rejection and inflammation at 6 months and 1 year\n* Changes in kidney function from the start of treatment\n* How many people have biopsy results showing their kidney tissue looks normal again\n* How long the transplanted kidney keeps working\n* How many participants have medical problems during the study\n* How many participants show signs of another type of kidney transplant rejection called T-cell-mediated rejection (TCMR) at Week 24 and Week 52\n* How do results from vital signs, electrocardiograms (ECGs), and blood and urine tests change over time\n* How felzartamab is processed by the body\n* How many participants develop antibodies against felzartamab in the blood\n\nThe study will be done as follows:\n\n* Participants will be screened to check if they can join the study. This will take up to 42 days.\n* There will be 2 parts in this study.\n* Part A of the study is "double blind." This means that neither the participants, study doctor, or site staff know if the participants received the study drug or a placebo. During Part A, participants will be randomized to receive up to 9 doses of either felzartamab or placebo.\n* Part B of the study is "open label." This means that the participants, study doctor, and site staff know which study drug the participant is receiving. During Part B, all participants from Part A will receive up to 9 doses of felzartamab.\n* All doses will be given through an "intravenous" infusion. This means it will be given into a vein. The dose the participants receive will depend on their body weight.\n* Part A will last up to 24 weeks. Part B will last up to 28 weeks. In total, participants will have up to 21 study visits and will be in the study for about 1 year.', 'detailedDescription': 'The primary objective of this study is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with active or chronic active AMR.\n\nThe secondary objectives of this study are: Part A: To evaluate the efficacy of felzartamab compared to placebo through additional clinical endpoints; Part B: To summarize felzartamab efficacy at Week 52 in kidney transplant recipients diagnosed with active or chronic active AMR; Parts A and B: To evaluate the safety of felzartamab in kidney transplant recipients diagnosed with active or chronic AMR and to assess the pharmacokinetic (PK) profile and immunogenicity of felzartamab.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Key Inclusion Criteria:\n\n* Active or chronic active AMR (biopsy-confirmed) without TCMR per central reading, as defined by the Banff 2022 criteria.\n* Kidney transplant at least 6 months prior to Screening visit (recipients of either living or deceased donors).\n* Donor-specific antibody (DSA): Human leukocyte antigen (HLA) Class I and/or II antigen-specific DSA-positive (preformed and/or de novo DSA) as determined by the local laboratory's definition of positivity using singleantigen bead-based assays within 3 months prior to randomization.\n\nKey Exclusion Criteria:\n\n* Transplant: Blood type (ABO)-incompatible transplant.\n* History of multiple organ transplants including en bloc and dual kidney transplants.\n* Acute, rapid decline in renal function, defined as a participant likely to require renal replacement therapy within the subsequent 30 days as determined by the Investigator.\n* Treatment: Prior AMR/TCMR treatment (with the exception of corticosteroids) within 3 months prior to randomization is excluded as listed below. Participants who received any of these treatments between 3 and 6 months prior to randomization must have both a renal biopsy (IC3) and DSA testing at least 6 weeks after completing (or stopping) treatment in order to confirm continuing AMR and to determine eligibility:\n\n 1. Intravenous or subcutaneous immunoglobulin (IVIg or subcutaneous immunoglobulin \\[SCIg\\]) or PLEX.\n 2. Complement system inhibitors (e.g., eculizumab).\n 3. Proteasome inhibitors (e.g., bortezomib).\n 4. Tocilizumab.\n 5. Any B cell-depleting therapy (including anti-Cluster of Differentiation 20 \\[CD20\\] agents \\[e.g., rituximab\\]) within 3 months prior to randomization.\n 6. Any other investigational agent within 3 months or 5 half-lives (whichever is longer) of randomization.\n\nNote: Other protocol-defined inclusion/exclusion criteria apply."}, 'identificationModule': {'nctId': 'NCT06685757', 'acronym': 'TRANSCEND', 'briefTitle': 'A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Biogen'}, 'officialTitle': 'A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)', 'orgStudyIdInfo': {'id': '299AR301'}, 'secondaryIdInfos': [{'id': '2024-519095-66-00', 'type': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Felzartamab', 'interventionNames': ['Drug: Felzartamab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Felzartamab', 'type': 'DRUG', 'otherNames': ['MOR202', 'MOR03087', 'TJ202', 'HIB202', 'BIIB148'], 'description': 'Participants will receive felzartamab by intravenous infusion.', 'armGroupLabels': ['Felzartamab']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Participants will receive 0.9% saline solution by intravenous infusion.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90033', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '800-872-2273'}, {'name': 'Maw Thin Thin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Southern California', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90048', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '310-423-3069'}, {'name': 'Edmund Huang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cedars-Sinai Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '310-794-8516'}, {'name': 'Suphamai Bunnapradist', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UCLA', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92868', 'city': 'Orange', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '714-771-8000'}, {'name': 'Yasir Qazi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Providence Healthcare', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '92408', 'city': 'San Bernardino', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '909-558-3636'}, {'name': 'Rafael Villicana', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Loma Linda', 'geoPoint': {'lat': 34.10834, 'lon': -117.28977}}, {'zip': '94109', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '415-600-1070'}, {'name': 'Ram V. Peddi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'California Pacific Medical Center', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '94143', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '415-353-1551'}, {'name': 'Puneet Sood', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of California, San Francisco', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '303-724-483'}, {'name': 'James Cooper', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Colorado', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '60637', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '773-702-0316'}, {'name': 'Beatrice Concepcion', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Chicago', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '66160', 'city': 'Kansas City', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '913-588-8239'}, {'name': 'Diane Cibrik', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Kansas', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '70112', 'city': 'New Orleans', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '504-503-7021'}, {'name': 'Diala Khirfan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Tulane University Health Sciences Center', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '734-763-1407'}, {'name': 'Mona Doshi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '507-293-2643'}, {'name': 'Carrie Schinstock', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mayo Clinic', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '63130', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '314-362-4109'}, {'name': 'Tarek Alhamand', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Washington University', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '68198-5331', 'city': 'Omaha', 'state': 'Nebraska', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '402-559-9315'}, {'name': 'Mannon Langewisch', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Nebraska', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '07039', 'city': 'West Orange', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '973-322-2146'}, {'name': 'Anup Patel', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cooperman Barnabas Medical Center', 'geoPoint': {'lat': 40.79871, 'lon': -74.23904}}, {'zip': '27705', 'city': 'Durham', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '919-613-6133'}, {'name': 'Scott Sanoff', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Duke University', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '45219', 'city': 'Cincinnati', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '513-558-6709'}, {'name': 'Steve Woodle', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Cincinnati', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '216-444-5383'}, {'name': 'Emilio Poggio', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cleveland Clinic', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '614-293-6883'}, {'name': 'Todd Pesavento', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'The Ohio State University', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '215-662-4643'}, {'name': 'Roy Bloom', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Penn Medicine - Hospital of the University of Pennsylvania', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '37232', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '615-936-1179'}, {'name': 'Anthony Langone', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Vanderbilt University', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '214-645-0444'}, {'name': 'David Wojciechowski', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UT Southwestern Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '713-441-6222'}, {'name': 'Osama Gaber', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Houston Methodist', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '23298', 'city': 'Richmond', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '804-828-1855'}, {'name': 'Gaurav Gupta', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Virginia Commonwealth University', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '98195', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '206-598-5896'}, {'name': 'Nicole Leca', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Washington Medical Center', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '414-805-6060'}, {'name': 'Matt Cooper', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Medical College of Wisconsin', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'zip': '3050', 'city': 'Parkville VIC', 'state': 'Australia', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Royal Melbourne Hospital'}, {'zip': '2145', 'city': 'Sydney', 'state': 'New South Wales', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Westmead Hospital', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': '6150', 'city': 'Murdoch', 'state': 'Western Australia', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Fiona Stanley Hospital', 'geoPoint': {'lat': -32.06987, 'lon': 115.83757}}, {'zip': 'QLD 4102', 'city': 'Woolloongabba', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Princess Alexandra Hospital', 'geoPoint': {'lat': -27.48855, 'lon': 153.03655}}, {'zip': '1090', 'city': 'Spitalgasse', 'state': 'Vienna', 'status': 'RECRUITING', 'country': 'Austria', 'contacts': [{'role': 'CONTACT', 'phone': '+43 (0)1 40400-43630'}, {'name': 'George A. Bohmig', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Medical University of Vienna'}, {'zip': '90020-090', 'city': 'Centro Histórico', 'state': 'Porto Alegre - RS', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'role': 'CONTACT', 'phone': '55 51 3214 8640'}, {'name': 'Valter Duro Garcia', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vicente Scherer', 'geoPoint': {'lat': -30.02813, 'lon': -51.22766}}, {'zip': '15090-000', 'city': 'Vila São José', 'state': 'São José Do Rio Preto', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'role': 'CONTACT', 'phone': '55 17 3201-5000', 'phoneExt': '5656'}, {'name': 'Mário Filho Abbed', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital de Base da Faculdade de Medicina de São José do Rio Preto', 'geoPoint': {'lat': -4.9481, 'lon': -60.23479}}, {'zip': '05403-010', 'city': 'Cerqueira César', 'state': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'role': 'CONTACT', 'phone': '55 11 2661 8089'}, {'name': 'Elias David Neto', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo', 'geoPoint': {'lat': -23.03556, 'lon': -49.16611}}, {'zip': '04038-002', 'city': 'Vila Clementino', 'state': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'role': 'CONTACT', 'phone': '+55 11 5087 8113'}, {'name': 'Silva Helio Tedesco', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Fundação Oswaldo Ramos - Hospital do Rim (HRIM)', 'geoPoint': {'lat': -23.59818, 'lon': -46.64393}}, {'zip': 'T6G 2C8', 'city': 'Edmonton', 'state': 'Alberta', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'role': 'CONTACT', 'phone': '587-598-2336'}, {'name': 'Sita Gourishankar', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Alberta', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'V5Z 1M9', 'city': 'Vancouver', 'state': 'British Columbia', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'role': 'CONTACT', 'phone': '604-875-5950'}, {'name': 'James Lan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Vancouver General Hospital', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'V6T 1Z3', 'city': 'Vancouver', 'state': 'British Columbia', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'role': 'CONTACT', 'phone': '604-682-2344'}, {'name': 'Gill John', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "The University of British Columbia (UBC)/St. Paul's Hospital part of Providence Health Care", 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'H3G 1A4', 'city': 'Montreal', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'role': 'CONTACT', 'phone': '514- 934-1934', 'phoneExt': '31951'}, {'name': 'Tchervenkov Jean', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'McGill University', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': '32000', 'city': 'Bordeaux', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'role': 'CONTACT', 'phone': '33 5 56 79 55 38'}, {'name': 'Lionel Couzi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Lyon Hôpital Edouard Herriot', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '38700', 'city': 'La Tronche', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'role': 'CONTACT', 'phone': '0033 5 56 79 55 38'}, {'name': 'Lionel Rostaing', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Grenoble Alpes Hôpital Michallon', 'geoPoint': {'lat': 45.20507, 'lon': 5.74629}}, {'zip': '69003', 'city': 'Lyon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'role': 'CONTACT', 'phone': '334 2785 8000'}, {'name': 'Olivier Thaunat', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospices Civils de Lyon - Hôpital Édouard Herriot', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '31400', 'city': 'Toulouse', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'role': 'CONTACT', 'phone': '33 5 61 32 32 00'}, {'name': 'Nassim Kamar', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital de Rangueil', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '10117', 'city': 'Berlin', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'role': 'CONTACT', 'phone': '4930450514002'}, {'name': 'Klemens Budde', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Charite University', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '1307', 'city': 'Dresden', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'role': 'CONTACT', 'phone': '0049 351 458 4233'}, {'name': 'Christian Hugo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitaetsklinikum Carl Gustav Carus Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '20246', 'city': 'Hamburg', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'role': 'CONTACT', 'phone': '+49 (0)40 7410-52240'}, {'name': 'Florian Grahammer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitatsklinikum Hamburg-Eppendorf', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '1023', 'city': 'Grafton', 'state': 'Auckland', 'status': 'RECRUITING', 'country': 'New Zealand', 'facility': 'Auckland City Hospital', 'geoPoint': {'lat': -36.86029, 'lon': 174.76566}}, {'zip': '8036', 'city': 'Calle Villarroel', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'role': 'CONTACT', 'phone': '34 93 227 5444'}, {'name': 'Fritz Diekmann', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Clinic de Barcelona'}, {'zip': '8003', 'city': 'Ciutat Vella', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'role': 'CONTACT', 'phone': '0034 93 248 31 62'}, {'name': 'Marta Barrio Crespo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital del Mar', 'geoPoint': {'lat': 41.38022, 'lon': 2.17319}}, {'zip': '8035', 'city': 'Horta-Guinardó', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'role': 'CONTACT', 'phone': '34934893000'}, {'name': 'Oriol Bestard Matamoros', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Hospital Universitario Vall d'Hebron", 'geoPoint': {'lat': 41.41849, 'lon': 2.1677}}, {'zip': '8907', 'city': "L'Hospitalet de Llobregat", 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'role': 'CONTACT', 'phone': '0034 93 260 73 85'}, {'name': 'Eduardo Melilli', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Universitario de Bellvitge', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'zip': '50009', 'city': 'Zaragoza', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'role': 'CONTACT', 'phone': '0034 976 765 624'}, {'name': 'Alex Dalmau', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Universitario Miguel Servet', 'geoPoint': {'lat': 41.65606, 'lon': -0.87734}}, {'zip': '4031', 'city': 'Petersgraben', 'state': 'Basel', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'role': 'CONTACT', 'phone': '0041 61 265 44 07'}, {'name': 'Matthais Diebold', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University Hospital Basel'}, {'zip': '8091', 'city': 'Zurich', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'role': 'CONTACT', 'phone': '41 44 255 33 84'}, {'name': 'Thomas Schachtner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitätsspital Zürich', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}], 'centralContacts': [{'name': 'US Biogen Clinical Trial Center', 'role': 'CONTACT', 'email': 'clinicaltrials@biogen.com', 'phone': '1-866-633-4636'}, {'name': 'Global Biogen Clinical Trial Center', 'role': 'CONTACT', 'email': 'clinicaltrials@biogen.com'}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Biogen'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/', 'ipdSharing': 'YES', 'description': "In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Biogen', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}